Sentiment for Insmed Inc (NASDAQ:INSM)
Insmed Inc (NASDAQ:INSM) institutional sentiment increased to 1.33 in Q4 2018. Its up 0.51, from 0.82 in 2018Q3. The ratio has increased, as 56 investment managers increased or started new equity positions, while 42 trimmed and sold holdings in Insmed Inc. The investment managers in our partner’s database now possess: 75.98 million shares, down from 76.71 million shares in 2018Q3. Also, the number of investment managers holding Insmed Inc in their top 10 equity positions was flat from 1 to 1 for the same number . Sold All: 12 Reduced: 30 Increased: 36 New Position: 20.
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company has market cap of $2.30 billion. The companyÂ’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It currently has negative earnings. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension.
The stock decreased 1.86% or $0.56 during the last trading session, reaching $29.62. About 738,597 shares traded. Insmed Incorporated (NASDAQ:INSM) has risen 22.92% since March 17, 2018 and is uptrending. It has outperformed by 18.55% the S&P500.
Analysts await Insmed Incorporated (NASDAQ:INSM) to report earnings on May, 1. They expect $-1.03 earnings per share, down 19.77 % or $0.17 from last year’s $-0.86 per share. After $-1.17 actual earnings per share reported by Insmed Incorporated for the previous quarter, Wall Street now forecasts -11.97 % EPS growth.
Foresite Capital Management Ii Llc holds 6.73% of its portfolio in Insmed Incorporated for 967,636 shares. Emerald Mutual Fund Advisers Trust owns 845,858 shares or 0.58% of their US portfolio. Moreover, Rock Springs Capital Management Lp has 0.53% invested in the company for 850,000 shares. The Indiana-based University Of Notre Dame Du Lac has invested 0.43% in the stock. Baker Bros. Advisors Lp, a New York-based fund reported 1.85 million shares.
Since January 1, 0001, it had 4 insider buys, and 2 insider sales for $610,461 activity.
Insmed Incorporated (NASDAQ:INSM) Ratings Coverage
Ratings analysis reveals 88% of Insmed’s analysts are positive. Out of 8 Wall Street analysts rating Insmed, 7 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $20 while the high is $56. The stock’s average target of $39.29 is 32.65% above today’s ($29.62) share price. INSM was included in 11 notes of analysts from October 1, 2018. The stock has “Buy” rating by Cowen & Co on Friday, February 22. H.C. Wainwright maintained Insmed Incorporated (NASDAQ:INSM) on Monday, February 25 with “Buy” rating. The firm has “Outperform” rating given on Monday, October 1 by Credit Suisse. Citigroup maintained the stock with “Neutral” rating in Tuesday, December 4 report. The stock of Insmed Incorporated (NASDAQ:INSM) earned “Overweight” rating by Morgan Stanley on Monday, October 1. The stock has “Buy” rating by Morgan Stanley on Monday, February 25. The stock of Insmed Incorporated (NASDAQ:INSM) has “Outperform” rating given on Friday, February 15 by JMP Securities. The rating was upgraded by Goldman Sachs on Thursday, January 17 to “Buy”. Canaccord Genuity maintained it with “Buy” rating and $44 target in Friday, March 8 report.
More notable recent Insmed Incorporated (NASDAQ:INSM) news were published by: Streetinsider.com which released: “Insmed (INSM) Misses Q4 EPS by 10c, Revenues Beat; Offers FY19 Revenue Outlook Above Consensus – StreetInsider.com” on February 22, 2019, also Prnewswire.com with their article: “Insmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019 – PRNewswire” published on February 15, 2019, Seekingalpha.com published: “Insmed wins FDA approval for lung disease treatment (updated) – Seeking Alpha” on September 28, 2018. More interesting news about Insmed Incorporated (NASDAQ:INSM) were released by: Nasdaq.com and their article: “Here’s Why Insmed Slumped Lower Today – Nasdaq” published on October 01, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For February 15, 2019 – Benzinga” with publication date: February 15, 2019.